0001161697-23-000243.txt : 20230407
0001161697-23-000243.hdr.sgml : 20230407
20230407170021
ACCESSION NUMBER: 0001161697-23-000243
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230405
FILED AS OF DATE: 20230407
DATE AS OF CHANGE: 20230407
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tierney David S
CENTRAL INDEX KEY: 0001292636
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33057
FILM NUMBER: 23809161
MAIL ADDRESS:
STREET 1: C/O ABLE LABORATORIES, INC.
STREET 2: 6 HOLLYWOOD COURT, CN 1013
CITY: SOUTH PLAINFIELD
STATE: NJ
ZIP: 07080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001369568
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 355 ALHAMBRA CIRCLE
STREET 2: SUITE 801
CITY: CORAL GABLES
STATE: FL
ZIP: 33134
BUSINESS PHONE: (305) 529-2522
MAIL ADDRESS:
STREET 1: 355 ALHAMBRA CIRCLE
STREET 2: SUITE 801
CITY: CORAL GABLES
STATE: FL
ZIP: 33134
FORMER COMPANY:
FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC.
DATE OF NAME CHANGE: 20110215
FORMER COMPANY:
FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc.
DATE OF NAME CHANGE: 20060719
4
1
form4.xml
FORM 4 FOR 04-05-2023
X0407
4
2023-04-05
0
0001369568
CATALYST PHARMACEUTICALS, INC.
CPRX
0001292636
Tierney David S
355 ALHAMBRA CIRCLE, SUITE 801
CORAL GABLES
FL
33134
1
0
0
0
0
Common stock, par value $0.001 per share
2023-04-05
4
M
0
30000
0.79
A
343541
D
Common stock, par value $0.001 per share
2023-04-05
4
S
0
30000
16.83
D
313541
D
Options to purchase common stock
0.79
2023-04-05
4
M
0
30000
0
D
2023-06-15
Common Stock
30000
280500
D
Dr. Tierney has advised the Company that the sale of shares was to pay the exercise price of the shares and to raise funds for personal reasons, and does not relate to any disagreements between Dr. Tierney and the Company on any matter relating to the Company's operations, policies or practices. Dr. Tierney remains a Director of the Company.
Shares were sold in various lots from $16.70 to $16.98 per share. The listed sales price represents a weighted average price for the shares sold.
The option was granted on June 15, 2016 and previously vested in two annual installments.
/s/ David S. Tierney
2023-04-07